Pseudotyped Lentiviral Vectors: One Vector, Many Guises by Joglekar, Alok V. & Sandoval, Salemiz
REVIEW ARTICLE
Pseudotyped Lentiviral Vectors: One Vector, Many Guises
Alok V. Joglekar1,{ and Salemiz Sandoval1,{
1Department of Biology and Biological Engineering, California Institute of Technology, Pasadena, California.
{These authors contributed equally to this work.
Viruses have evolved specialized molecular mechanisms to transfer their genome efficiently into host cells.
Viruses can be repurposed into viral vectors to achieve controlled gene transfer to desired cells. One of
the most popular classes of vectors, lentiviral vectors (LVs), transduce mammalian cells efficiently. LVs are
pseudotyped with various heterologous viral envelopes to alter their tropism. While the most common
example is the envelope glycoprotein from vesicular stomatitis virus (VSVG), many other viral proteins have
also been used. Pseudotyping LVs with a diverse set of naturally occurring or engineered viral envelopes has
allowed targeted transduction of specific cell types. Many exciting studies are further uncovering new
specificities and shortcomings of pseudotyped LVs. These studies will expand the toolbox to make LVs that
cater to the specific requirements of transduction. This review provides a comprehensive overview of various
viral envelope pseudotypes used with LVs, their specificities, advantages, and drawbacks.
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LENTIVIRAL VECTORS
VIRAL VECTORS HAVE LONG been the tool of choice for
transferring genetic material to cells because they
have evolved specialized molecular mechanisms of
gene transduction. One of themost prominent types
of vectors, Lentiviral Vectors (LVs), are often the
preferred viral delivery systems for various pur-
poses. LVs have several advantages over other gene
transfer vectors: (1) they integrate irreversibly into
the host genome, therefore providing sustained
transgene expression that heritable upon cell divi-
sion; (2) they are engineered to package relatively
large payloads; (3) they show low immunogenicity
due to absence of all viral coding genes; (4) they are
extensively engineered to increase biosafety; and
(5) they can be pseudotyped with numerous heter-
ologous envelope glycoproteins. LV design evolved
conceptually from oncoretroviral vectors, which
were first used to introduce genetic material into
cells. Originally, these vectors were derived from
the Moloney Murine Leukemia Virus (MoMLV).
They were replication competent viruses that could
not infect nondividing cells, and were susceptible
to silencing and insertional oncogenesis. A solution
to transduce nondividing cells efficiently was pre-
sented when LVs were first developed in the
1990s.1–3 Lentiviruses are a family of retroviruses
that are capable of infecting and integrating into
nondividing cells. LVs were first constructed
by ‘‘gutting’’ the Human Immunodeficiency Virus
(HIV) genome and supplementing it with HIV
polyproteins in trans.3 Since then, a series of mod-
ifications to the vector genome have helped optimize
vector design to transduce nondividing cells while
improving the production and safety of the vectors.
FROM CD4 TROPISM OF HIV
TO BROAD TROPISM OF VESICULAR
STOMATITIS VIRUS
The HIV envelope glycoprotein, a class I fusion
protein, is generated by cleavage of the precursor
gp160 in two subunits: outer membrane protein
gp120, and inner membrane protein gp41. The
HIV envelope consists of three gp120/gp41 hete-
rodimers. HIV binds to the surface of cells by bind-
ing to its primary cellular surface receptor: CD4
and co-receptors CXCR4 or CCR5.4–6 Binding of
gp120 to CD4 and CXCR4/CCR5 leads to a change
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in conformation of gp41, facilitating target cell
membrane fusion and viral entry. Because the HIV
envelope preferentially recognizes the human CD4
receptor, early infections necessitated the expres-
sion of CD4 on the surface of target cells, limiting
the tropism to CD4+ T cells and monocytes.
To circumvent this problem, Burns et al. pseu-
dotyped the early onco-viral vectors based on Mu-
rine LeukemiaVirus (MLV)with the glycoprotein of
the Vesicular Stomatitis Virus (VSV), VSVG.7 VSV
is a member of the Rhabdoviridae family, which
consists of single-stranded, negative-sense RNA
viruses. VSVG is a trimeric protein that binds to its
cellular receptor and facilitates endocytosis of the
virus. Acidification (decrease in pH) of the endo-
somes triggers conformational changes in VSVG
that allow fusion with the cell membrane. Phos-
phatidylserine and low-density lipoprotein receptor
(LDLR) have been considered as the viral recep-
tor for VSVG.8 VSVG viral pseudotyping has now
become the mainstay in lentiviral production.7
VSVG-LVs have extremely broad tropism and can
transduce many cell types. VSVG pseudotyped LVs
are also stable and can withstand ultracentrifuga-
tion, allowing generation of high-titer LV prepara-
tions. These two properties of the VSVG envelope
have facilitated transduction of very difficult to
transduce cells such as stem cells and neurons.9,10
However, there are a few shortcomings to using the
VSVG envelope. VSVG-LVs transduce resting lym-
phocytes inefficiently, primarily because of low
LDLR expression levels.11 At high concentrations,
VSVG can be highly toxic to both producer cells and
the transduced cells. Therefore, generation of
packaging cell lines has been difficult, as sustained
VSVG expression is not viable. Nevertheless, stable
viral packaging cell lines that express VSVG from
inducible promoters have been used successfully to
package vectors.12–14 Another limitation is that
VSVG-LVs are inactivated by serum, making their
in vivo administration ineffective.15 Additionally,
because of their broad tropism, VSVG-LVs trans-
duce unwanted cells after systemic in vivo deliv-
ery.16 Due to these reasons, there has been a
significant body of research exploring alternative
envelopes for pseudotyping LVs to achieve: (1) tar-
geted cell tropism, including hard-to-transduce
cells, (2) low cytotoxicity during transduction and
vector packaging, and (3) resistance to serum inac-
tivation and ultracentrifugation. The subsequent
sections provide an overview of various strategies
used to overcome the limitations of VSVG. These
results are summarized in Table 1.
Some of the research in pseudotyping LVs has
examined closely related vesiculoviruses, such as
Chandipura (CNVG) and Piry (PRVG) strains of
VSV. These viruses, while related to VSV, have dif-
ferent cellular tropisms. LikeVSVG, these envelopes
are able to withstand high-speed centrifugation and
aremore resistant to serum inactivation.17However,
compared to VSVG-LVs, they do not transduce blood
cells as efficiently.17 CNVG-LVs, for example, are
more neurotropic, showing higher transduction into
neuroblastoma cells compared to VSVG. VSVG-LVs
outperform CNVG-LVs and PRVG-LVs in trans-
duction of CD4+ and CD8+ T cells, NK cells, and
CD34+ hematopoietic stem cells (HSCs).18,19 Envel-
ope from another closely related virus, Cocal virus,
exhibits broad tropism similar to VSVG. Cocal-LVs
show higher transduction efficiencies in human and
nonhuman primate CD34+ HSCs and CD4+ T cells,
and higher resistance to serum inactivation com-
pared to VSVG-LVs.20 Additionally, several studies
have attempted to engineer VSVG to increase its
serum stability. VSVG variants generated by mu-
tagenesis libraries that are resistant to a panel of
human and animal sera and that are thermostable
were identified by Schafer et al.21
RETROVIRAL ENVELOPES
Perhaps the most ‘‘obvious’’ extension of to pseu-
dotyping LVs is to use envelopes from their close
relatives in the Retroviridae family. Indeed, nu-
merous studies have demonstrated pseudotyping of
LVs with envelopes from other retroviruses such as
MLV,22–24 Gibbon Ape Leukemia Virus (GALV),25,26
Feline Leukemia Virus (RD114),26–29 Amphotropic
Retrovirus (Ampho),30–32 10A1 MLV (10A1),33,34
and Ecotropic retrovirus (Eco).31,34,35 Retroviruses
are generally conserved in their genome and virion
structure. Retroviral envelope glycoproteins attach
to their receptors and fuse directly to the host-cell
membrane. Retroviral envelope glycoproteins are
synthesized as a single polypeptide, which is
cleaved by the viral protease into two subunits:
surface (SU) and transmembrane (TM). Fully ma-
ture envelopes are made up of heterotrimers of SU
and TM. SU subunits are heavily glycosylated,
which facilitates binding to their receptors. TM
proteins consist of three domains: an N-terminal
ectodomain, a membrane-spanning domain, and a
cytoplasmic tail. SU-receptor binding triggers a
conformational change in the TM protein, allowing
insertion of the ectodomain into the host-cell
membrane, leading to fusion.36 The membrane-
spanning domain anchors the viral and cellular
membranes, whereas cytoplasmic tails interact
with thematrix (MA) protein. Despite considerable
sequence variability, the organizational structure
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of retroviral envelopes is conserved. While theo-
retically modular, combinations of vectors with
heterologous envelope glycoproteins are not al-
ways compatible. For instance, Ampho or 10A1
pseudotype HIV-1-based LVs efficiently, whereas
wild-type GALV does not. In contrast, all three en-
velops, Ampho, 10A1, and GALV, can pseudotype
MLV-based retroviral vectors efficiently.31 Lack of
compatibility with a heterologous vector is depen-
dent upon the cytoplasmic tails of the envelopes. In
some cases, co-expression of heterologous gag pro-
teins hinders the processing of envelope or its co-
localization with the capsid.36 These deficiencies
can often be rescued by partially replacing the cy-
toplasmic tail of the envelope with that from an-
other virus. For instance, GALV envelope with
either truncated or chimeric C-terminal show 104
fold enhancement in lentiviral titers due to effi-
cient processing. Simian immunodeficiency virus–
based LVs pseudotyped with RD114 envelop are
not packaged efficiently. Partial replacement of the
TM regionwith that fromMLV (RD114-TR) results
in efficient co-localization of envelope and capsid,
leading to faster maturation of viral particles and
efficient virion packaging.36
The diverse tropisms offered by various retrovi-
ral envelopes combined with the ability of lenti-
viruses to transduce nondividing cells and lower
risk of insertionalmutagenesismakes a compelling
argument for RV-pseudotyped LVs. Indeed, LVs
pseudotyped with heterologous retroviral enve-
lopes have been used extensively. Notably, LVs
pseudotyped with MLV and Eco envelope trans-
duce murine cells efficiently. Of particular impor-
tance to gene therapy are LVs pseudotyped with
GALV or RD114-TR envelopes.27,29 Several studies
Table 1. Summary of viral envelopes described in this study and their tropisms
Virus Envelope Receptor Cell type specificity Reference
Human immunodeficiency virus (HIV) gp160 (gp41 and gp120) CD4, CCR5/CXCR4 T cells, monocytes 4–6
Retroviruses
Murine leukemia virus (MLV) gp70 (SU and TM) mCAT-1 Hematopoietic cells, fibroblasts 22–24
Gibbon ape leukemia virus (GALV) gp70 (SU and TM) Pit1 Hematopoietic cells 25,26
Feline leukemia virus (RD114) gp70 (SU and TM) SLC1A5, hASCT2 Hematopoietic cells 26–29
Amphotropic retrovirus (Ampho) gp70 (SU and TM) RAM1 Hematopoietic cells 33,34
10A1 MLV (10A1) gp70 (SU and TM) Pit1, Pit 2 Hematopoietic cells 33,34
Ecotropic retrovirus (Eco) gp70 (SU and TM) Rec1 Hematopoietic cells 31–35
Baboon ape leukemia virus (BaEV) gp70 (SU and TM) hASCT2 Hematopoietic cells 38,39
Paramyxoviruses
Measles virus (MV) H and F CD46, SLAM Lymphocytes, dendritic cells 41–44
Nipah virus (NiV) H and F EphrinB2 Embryonic stem cells, hematopoietic
stem cells
49,50
Rhabdoviruses
Rabies virus (RabV) G P75NTR, NCAM, nAchR Neural cells 51,57–60
Mokola virus (MOKV) G Not known Neural cells 61,62
Ebola Zaire virus (EboZ) G NPC1, TIM1 hematopoietic cells, lung epithelial cells 62,63
Lymphocytic choriomeningitis
virus (LCMV)
GP1 and GP2 a-dystroglycan Dendritic cells, neural cells, hepatocytes 64–67
Baculovirus GP64 Heparan sulfate, phospholipids Fibroblasts, hepatocytes, epithelial cells 68–70
Alphaviruses
Chikungunya virus (CHIKV) E1 and E2 Potential involvement of heparin
sulfate and integrins
Hematopoietic cells, fibroblasts,
hepatocytes
72,73,78,79
Ross River virus (RRV) E1 and E2 Potential involvement of heparin
sulfate and integrins
Fibroblasts, neuroglial cells, hepatocytes,
Kupffer cells
72
Semliki Forest virus (SFV) E1 and E2 Potential involvement of heparin
sulfate and integrins
Fibroblasts, neuroglial cells, hepatocytes,
Kupffer cells
72
Sindbis virus (SV) E1 and E2 Potential involvement of heparin
sulfate and integrins
Hematopoietic cells, fibroblasts, hepatocytes 77
Venezualan equine encephalitis
virus (VEEV)
E1 and E2 Potential involvement of heparin
sulfate and integrins
Fibroblasts, hepatocytes 77
Western equine encephalitis
virus (WEEV)
E1 and E2 Potential involvement of heparin
sulfate and integrins
77
Orthomyxoviruses
Influenza A-D HA Sialic acid Airway epithelia 80
Fowl Plague Virus (FPV) HA Sialic acid Airway epithelia 81
Vesiculoviruses
Vesicular stomatitis virus VSV-G LDLR Broad tropism 7,8
Chandipura virus and Piry virus CNV-G and PRV-G not known Neural cells 17–19
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have shown that GALV/RD114-TR pseudotyped
vectors can transduce human CD34+ hematopoi-
etic stem/progenitor cells at high levels and with
minimal cytotoxicity.25,37 Moreover, these enve-
lope proteins are sufficiently stable to allow vector
concentration by ultracentrifugation. Another en-
velope of interest is the Baboon Endogenous Ret-
rovirus Envelope (BaEV), which has been shown to
pseudotype LVs effectively for gene transfer into
humanHSCs. The BaEV envelope uses two surface
receptors, the neutral amino acid transporters
ASCT-1 and ASCT-2, for entry into the cell. Unlike
VSV-G, which requires the upregulation of the
LDLR by pre-stimulation with a high concentra-
tion of cytokines, BaEV receptors are already ex-
pressed at basal levels in humanHSCs. This allows
for gene transfer without the need for activation of
HSCs, retaining their stem-ness andmultipotency.
Verhoeyen et al. showed that BaEv-LVs led to a
significantly higher level of transduction compared
to VSVG-LVs, without the need for pre-stimulation.
BaEV-transduced HSCs also showed long-term
engraftment and effective multi-lineage potential
in immunocompromised mice using lower amounts
of cytokines. Therefore, BaEV-LVs are potentially
superior to VSVG-LVs for gene therapy using
HSCs.38 BaEV-LVs were also recently shown to be
more than 10-fold more efficient at transducing
primary human B cells compared to VSVG-LVs
upon B cell receptor-mediated stimulation.39
PARAMYXOVIRAL ENVELOPES
A well-studied envelope used for pseudotyping
comes from themeasles virus (MV).40MV is a single-
stranded, negative-sense RNA virus from the Para-
myxoviridae family. Humans are the sole natural
hosts of MV, which causes measles, a respiratory
infection. MV relies on cell–cell fusion for transmis-
sion of virus. As with other paramyxoviruses, MV
has hemagglutinin (H) on its surface. Although
there are eight clades of MV, they share a single H
serotype. MV fusion with the cell membrane is me-
diated by its fusion protein (F). MV-F is a type 1
membrane protein, which mediates pH independent
fusion by cleavage of its ectodomain into two sub-
units. MV-H interacts with the cleaved F trimers
through itsmembrane proximal regions and triggers
fusion. Therefore, presence of both H–F is essential
for formation of fusogenic complexes. Several reports
have shown thatHIV-based LVs can be pseudotyped
effectively with MV-H-F.40,41 The cytoplasmic tail of
H–F complexes interacts with the HIV capsid pro-
tein, allowing attachment and fusion of pseudotyped
vectors. MV-pseudotyped LVs have shown to be par-
ticularly useful for transducing cells of hematopoietic
origin.41–43 Receptor usage by MV-LVs depends on
the strains from which the envelopes are derived.
The cellular receptors for H are CD46 and signaling
lymphocyte activation molecule (SLAM).44 CD46
is expressed on all human nucleated cells, where-
as SLAM is expressed constitutively on CD45ROhi
memory T cells, immature thymocytes, B cells, mac-
rophages, and dendritic cells (DCs). LVs pseudo-
typed with envelope from wild-type (WT-MV) or
Edmonston vaccine (EdM-MV) strain showed dif-
ferential usage of receptors across several cell lines:
CD46 binding was sufficient for EdM-MV, whereas
WT-MV required both CD46 and SLAM on the cell
surface. Moreover, for WT-MV, binding of H pro-
teins to both CD46 and SLAM on the same cell was
essential for transduction.44,45 TheEdM-MV strain
is better suited for pseudotyping LVs because it can
attach to either CD46 or SLAM, unlike WT-MV,
which required both receptors to be present. EdM-
MV-LVs transduce restingBandT cells significantly
more efficiently than VSVG-LVs, and stimulated or
activated lymphocytes as efficiently. Resting lym-
phocytes are notoriously difficult to transduce with
VSVG-LVs due to low LDLR expression, and MV-
LVs provide an excellent alternative.11 MV-LVs also
showed better transduction of DCs, which coincides
with high CD46 expression.41,44,46 Moreover, the
presence of Dendritic Cell-Specific Intracellular ad-
hesionmolecule-3-GrabbingNon-integrin (DC-SIGN)
on DCs enhances transduction. DC-SIGN is not
sufficient cell entry, but rather enhances infection
of MV. Furthermore, transduction with MV-LVs
did not cause maturation of DCs, unlike VSVG-
LVs, which increases their utility to transduce
DCs.47 MV-LVs can also be concentrated using
high-speed centrifugation or ultracentrifugation, al-
lowing generation of high-titer vectors preparations.
Recently, Mustang-Q column chromatography was
used to concentrate MV-LVs, demonstrating their
clinical utility.48 A remarkable example of highly
specific tropism comes from another paramyxovirus,
Nipah Virus (NiV).49,50 NiV is a zoonotic virus, with
fruit bats as its primary hosts. NiV can infect
humans, resulting in multiple, potentially fatal
flu-like symptoms as well as encephalitis. NiV
envelope ismadeup of F andGglycoproteins.NiV-G
binds its receptor, EphrinB2, with high affinity and
causes conformational changes that lead to NiV-F-
mediated fusion and viral entry. EphrinB2 is ex-
pressed on several multipotent and pluripotent
cells such as murine embryonic stem cells, human
HSCs, and human neural stem cells. Therefore,
pseudotyping with NiV-F-G can be of great use,
especially to transduce these difficult to transduce
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cells. NiV-F-G can pseudotype LVs efficiently, espe-
cially upon deletion of parts of the F and G proteins.
NiV-LVs transduce multipotent and pluripotent
stem cells with high efficiency both in vitro and
in vivo. Another unique feature of NiV-LVs is that
they are not shunted into the liver sink upon sys-
temic administration inmice, unlike VSVG-LVs.49,50
RHABDOVIRAL ENVELOPES
Rabies virus (RabV) is a single-stranded
negative-sense RNA virus from the Rhabdoviridae
family. RabV has a broad range of host tropism,
including humans, rodents, and bats. RabV causes
infections of the central nervous system (CNS) that
is often fatal. Like VSV, RabV uses its envelope
glycoprotein (RabVG) for attachment to the host-
cell surface and for mediating viral entry. The
receptors for RabVG are neurotrophic receptor
(p75NTR), Neural Cell AdhesionMolecule (NCAM),
and nicotinic acetylcholine receptor (nAChR), which
are all expressed on neural cells.51 Upon binding its
receptor, RabV enters the cell via Clathrin-mediated
endocytosis that is dependent on the RAB5 protein.
During maturation of endosomes to lysosomes, re-
duction in pH triggers fusion and entry. Neuro-
tropism of RabVGmakes it an attractive envelope to
pseudotype LVs for transduction of neuronal cells.
RabV-LVs mediate efficient transduction of neurons
in vitro and in vivo.52–57 RabV-LVs are able to move
from the axonal surfaces to the nucleus via retro-
grade transport mediated by dynein motor complex.
RabV-G co-localizes with its receptors, which shuttle
to the neuronal soma via retrograde transport, al-
lowingRabV-LVs to access thenucleus. AsRabVand
VSV are closely related, chimeric proteins created by
fusing parts of VSVG and RabVG can also pseudo-
type LVs. These fusion proteins (FuG-A/B/B2/C/E)
show different tropism and retrograde transport ef-
ficiencies. In particular,HiRet (FuG-B/B2) andFuG-
E are highly efficient at transduction and retrograde
transport.57–60 The G protein from a related Rhab-
dovirus, Mokola virus (MOKV-G), also shows simi-
lar ability to pseudotype LVs. MOKV infects cats
and other sub-Saharan mammals, but rarely hu-
mans. MOKV-G shares antigenic serotype with
RabV but shows broader tropism. MOKV-LVs
transduce a broad variety of cells in murine brain
upon in vivo transduction.19,30,61,62 Another viral
envelope that has been tested along with RabV is
from the highly pathogenic Ebola virus Zaire (EboZ).
EboZ belongs to the Filoviridae family, and causes
highly morbid hemorrhagic fevers. Primary hosts
and reservoirs of EboZ are various species of bats,
with primates and humans being end hosts. EboZ is
a large negative-sense, single-stranded RNA virus.
EboZ envelope consists of heavily glycosylated en-
velope glycoproteins that mediate both attachment
and entry. The putative receptors forEboZareNPC1
(Niemann–Pick C1, a lysosomal cholesterol trans-
porter) and TIM1 (T-cell Immunoglobulin and Mu-
cin domain 1, a receptor for phosphatidylserine),
which are expressed on T cells and other hemato-
poietic cells. EboZ-LVs can transduce lung epithelial
cells, skin fibroblasts, and epidermal progenitor cells
at comparable levels to VSVG-LVs.62,63 EboZ-LVs
also showed predominantly apical specificity for
transduction. However, high levels of cell decay and
death hampers their utility. Another concern in us-
ing Filoviral envelopes is their high biosafety risk, as
they are highly pathogenic.
LYMPHOCYTIC CHORIOMENINGITIS
VIRUS ENVELOPE
Lymphocytic ChorioMeningitis Virus (LCMV) is a
negative-sense, single-stranded RNA virus belong-
ing to the family Arenaviridae. The primary hosts
and reservoirs of LCMV are mice, but hamsters and
other rodents can propagate and transmit the virus.
LCMV can also infect dogs, pigs, primates, and even
humans. In rodents, LCMV causes inflammation of
the meninges due to lymphocytic infiltrates, which
can be fatal inmice. LCMVhas beenwell-studied for
its ability to induce robust CD8+ T cell responses
in infected hosts.19,64–66 The receptor for LCMV is
a-dystroglycan, which is expressed mainly on DCs,
with low levels of expression on neural cells and
hepatocytes. LCMV envelope glycoprotein is cleaved
into two subunits: GP1, a peripheral receptor bind-
ing subunit, andGP2, an integralmembrane protein
that anchors the virus and facilitates entry. LCMV-
LVs can transduce murine DCs, astrocytes, neural
progenitors, and glial cells. Although both VSVG-
LVs and LCMV-LVs can transduce cells of the CNS,
their tropisms differ.62,67 Upon in vivo injection,
LCMV-LVs transduce astrocytes, whereas VSVG-
LVs transduce neurons.62,67 LCMVs can also trans-
duce human and murine hepatocytes. In addition to
wide tropism, LCMV-LVs are amenable to concen-
tration of ultracentrifugation and to production us-
ing a packaging cell line.64,65
BACULOVIRUS ENVELOPE
Baculoviruses make an intriguing source of en-
velopes for pseudotyping LVs. Members of the
family Baculoviridae infect >600 species of inver-
tebrate animals, including arthropods and lepi-
doptera. Baculoviruses are double-stranded DNA
viruses that rely on one envelope glycoprotein for
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attachment and fusion. The most well-studied ba-
culoviral envelope protein isGP64 fromAutographa
californica. While a single receptor for GP64 has
not been identified, it is known that it interacts
with phospholipids on mammalian cells and that
heparan sulfate is essential for mammalian cell
transduction.68–70 Homotrimeric GP64 interacts
with CD55 in lipid rafts and induces fusion at low
pH. The actual mechanism for endocytosis is not
clear, and may involve both Clathrin-dependent
and Clathrin-independent pathways. LVs pseudo-
typed with GP64 (GP64-LVs) exhibit broad tropism
in mammalian cells.68–70 GP64-LVs can transduce
BHK, MDCK, HeLa, Huh7, and 293T cells at levels
comparable to VSVG-LVs. They show lower trans-
duction of certain cell lines, for example HepG2
and HT1080, than VSVG-LVs do. GP64-LVs are
particularly inefficient at transducing cells of he-
matopoietic origin such as K562, MOLT4, Raji, and
CEM cells. Efficient transduction of hepatocytes
makes GP64-LVs attractive candidates for gene
therapy for liver diseases. Indeed, in vivo injections
of GP64-LVs expressing factor VIII result in long-
term correction of hemophilia. In addition, GP64-
LVs were able to transduce airway epithelial cells
upon intranasal transduction in mice.71 GP64
envelopes are also sufficiently stable to withstand
ultracentrifugation and sufficiently less toxic, com-
pared to VSVG, to allow production from a packag-
ing cell line.
ALPHAVIRAL ENVELOPES
Ross River virus (RRV), Semliki Forest virus
(SFV), Chikungunya virus (CHIKV), Sindbis virus
(SV), Venezuelan Equine Encephalitis virus (VEEV),
and western equine encephalitis virus (WEEV)
are all alphaviruses that belong to the family
Togaviridae. Alphaviruses are mosquito-borne
viruses that infect humans and cause immuno-
inflammatory manifestations. Alphaviruses are
small positive-sense, single-stranded RNA viru-
ses with an icosahedral capsid. The alphavirus
envelope is heterodimeric, consisting of two gly-
coproteins: fusion protein E1 and receptor binding
protein E2. Alphaviral envelopes attach to their
target cells and undergo pH-dependent fusion. The
cellular receptors of the different Alphaviruses are
not known, but heparan sulfate and integrins are
thought to play a role in binding. Moreover, C-type
lectins DC-SIGN and DC-SIGNR enhance infec-
tion of alphaviruses in a glycosylation-dependent
manner, without being direct receptors of the en-
velope. The tropism of E1 can be altered by point
mutations, especially in case of CHIKV. Alphavirus
E1/E2 pseudotyped LVs were shown to exhibit
broad tropism in human cell lines. Feline immu-
nodeficiency virus (FIV)-based vectors pseudo-
typed with RRV and SFV transduced a multitude
of adherent and non-adherent cell lines.72 These
vectors transduced HT1080 and MDA231 cells
at efficiencies comparable to VSVG and THP1
and K562 cells at slightly lower efficiencies. RRV-
and SFV-LVs are not efficient at transduction of
other hematopoietic cells, includingCD34+ cells.72,73
RRV- and SFV-LVs transduce neuroglial cells
(astrocytes and oligodendrocytes) better thanVSVG-
LVs upon intracranial injections in mice.74–78 Sys-
temic administration of these viruses results in
high-level transduction of hepatocytes and Kupf-
fer cells. HIV-based CHIKV-LVs also show broad
tropism and transducemultiple cell types at levels
comparable to VSVG-LVs. Interestingly, transduc-
tion of monocytic THP1 cells enhances significantly
upon their differentiation into macrophages.78,79
This is possibly due to enhanced expression of viral
receptors on their surface. Unlike RRV-LVs,WEEV-
LVs and VEEV-LVs show much lower titers when
pseudotyped.77 LVs pseudotyped with SV envelope
are a fascinating case that demonstrates the versa-
tility of alphaviruses. As discussed in the sections
below, a small peptide inserted in SV envelope gly-
coprotein allows for attaching a customizable tar-
geting moiety to achieve specific transduction.
ORTHOMYXOVIRAL ENVELOPES
Influenza viruses such as influenza A–D and fowl
plague virus (FPV) belong to the family Orthomyx-
oviridae. These viruses exhibit diverse tropism, in-
cluding humans, pigs, horses, and fowl, and cause
respiratory infections that can be fatal. Orthomyx-
oviruses are negative-sense, single-stranded RNA
viruses. The envelopes of orthomyxoviruses are
made up of three proteins: hemagglutinin (HA),
which binds to sialic acid on the host cell, neur-
aminidase (NA), which releases virions from sialic
acid on producer cells and mediates fusion, and M2,
a proton channel that regulates pH-dependent viral
fusion. HA is proteolytically cleaved into HA1 and
HA2 subunits, exposing the fusion domain on HA2.
M2 protein is a homotetrameric protein that forms a
proton channel, which buffers the cellular com-
partments. Modulation of pH by M2 is essential for
both fusion and viral production. During early in-
fection, lowering of pH byM2 triggers HA-mediated
fusion, whereas during viral production, raising
of pH by M2 protects HA in nascent viral parti-
cles from inactivation.80 Because of its tropism, HA
can be used to pseudotype LVs for targeting airway
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epithelial cells. LVs pseudotyped with FPV HA
show low titers compared to VSVG.81 The titers can
be enhanced by co-expression of the NA and M2
proteins. While NA expression releases nascent vi-
rions efficiently, M2 expression increases the
amount of HA incorporated into virions.80 FPV-
LVs also show preferential transduction of apical
surface of airway epithelia, making them useful for
lung gene therapy.
TARGETED PSEUDOTYPING
While the viral envelopes described above have
diverse tropism, their specificity depends on the
envelope binding properties that have evolved to
infect different cell types. In recent years, several
groups have developed targeted approaches for
transducing specific cell types. These approaches
include pseudotyping viruses with engineered en-
velopes that are more tropic toward a cell type or
using proteins or antibodies that bind specifically
to the cell of interest. An instance of altering tro-
pism was demonstrated by selection of feline leu-
kemia virus (FeLV) envelope for mutants with
altered tropism. A more rational approach was
designed to introduce mutations in the FeLV en-
velope by site-directed mutagenesis, followed by
selection of viruses that bind the target cell line.
Through this approach, FeLV mutants with al-
tered tropism were identified.82–84 A more directed
approach for modifying the tropism of envelopes
takes advantage of specific ligand–receptor reac-
tions. Such a ligand-based approach was demon-
strated by incorporating a protein called heregulin
inMo-MLV virus envelope glycoprotein. Heregulin
binds specifically to HER2, a protein expressed on
breast cancer cell lines. The chimeric heregulin-
MoMLV envelopes were able to target breast can-
cer cells efficiently, demonstrating the feasibility
and efficacy of this approach.85 A similar approach
used a CD4-binding Designed Ankyrin Repeat
Protein (DARPin) linked to MV-H protein to target
LVs to CD4+ T cells.86 An even more targeted and
perhaps universal approach relies on using anti-
bodies to specific surface proteins to provide tar-
geting. Successful cell targeting has been achieved
using a modified Sindbis virus m168 envelope. The
envelope was modified to swap the receptor-
binding domain with an Ig-binding ZZ domain de-
rived from staphylococcus protein A, as well as to
mutate several residues to inactivate receptor-
binding sites. This envelope can be conjugatedwith
an antibody of choice, which allows targetable
binding to cells bearing the cognate epitope. The
antibody targets the virus to cells expressing its
epitope, and the envelope glycoprotein facilitates
fusion. This approach was successfully demon-
strated using an antibody against CD20 to specifi-
cally transduce B cells in vitro and in vivo.87
Similar approaches to target difficult to transduce
hematopoietic progenitors were developed using
the antibodies for CD133 and ABCG2.88 Antibody-
mediated transduction of total cord blood using
antibodies against CD133 or ABCG2 was moder-
ately enhanced in the presence of the antibody,
without the need for purification of progenitors. In
a similar approach, m168 envelopes conjugated
with single-chain antibodies against CD20, DEC-
205, and P-glycoprotein were used to target B cells,
DCs, and melanoma cells, respectively.89 A similar
approach was used to modify MV-H protein by
linking it to an antibody against CD8, to target the
vectors to CD8+ T cells.90 Retargeted MV-LVs to
recognize CD19 or CD20 were shown to be effective
in targeting B cells without activating them.91 MV-
LVs retargeted to recognize CD133 transduced
hematopoietic progenitors efficiently, whereas
those retargeted to CD105 transduced endothelial
cells efficiently. The flexibility of MV-H protein to
accommodate heterologous targeting moieties
makes it an attractive option to act as a platform for
specifically targeting LVs.92 There is a great ben-
efit to uncoupling the antibody and fusogenic pa-
rameters in the studies listed above because it
allows the two parameters to be optimized sepa-
rately. However, incorporation of the targeting
antibody in a non-covalent manner is not as effi-
cient. Modification of MV-H proteins overcomes
these limitations and confers flexibility to target a
wide range of desired cell types. As this powerful
tool evolves over time, its limitations as well as full
potential will be clear. The related paramyxovirus
NiV was also demonstrated to be amenable to in-
corporation of targeting domains. Recently, re-
targeting of NiV-G glycoprotein by ablating its
binding to EphrinB2, and by incorporating DAR-
Pins or scFvs was demonstrated. NiV-LVs re-
targeted to EpCAM, CD8, CD117, or GluA4 were
used successfully.93 These reports demonstrate
that in the recent years, largely due to the tre-
mendous flexibility of paramyxoviral envelopes,
targeting of LVs to specific cell types has become
more feasible and efficient.
VECTOR MANUFACTURING
CONSIDERATIONS
The suitability of LVs for clinical gene therapy
has prompted advances in theirmanufacture using
good manufacturing practices (GMP). GMP-grade
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vector production requires that vectors prepara-
tions be consistently of high quality, in addition to
being safe and sterile for clinical use. While pack-
aging cell lines have been tested, transient trans-
fection of 293T cells seems to be the method of
choice tomake clinical grade LVs.Not surprisingly,
the majority of the development of GMP-grade
vector production has focused on VSVG-LVs. As
mentioned before, VSVG-LVs are able to withstand
ultracentrifugation and column chromatography
for concentration and are resistant to freeze–
thawing,94 which is needed for efficient gene
transfer in primary cells under GMP conditions.
Following transient transfection, a semi-closed
manufacturing process is often employed to main-
tain sterility and avoid vector loss.95,96 The vector
preparation is treated with Benzonase to remove
DNA. This is followed by ultrafiltration, tangential
flow filtration, or chromatography using Mustang-
Q or similar columns. These methods not only
concentrate the virus, but also remove potentially
toxic or immunogenic cellular debris from the
producer cells. The vector prep then goes through
quality control, ensuring that the preparation is
sterile, is at sufficient titers, and is replication in-
competent. In addition to VSVG-LVs, several other
varieties of pseudotyped LVs are amenable to
GMP-grade manufacturing. MV-LVs have also
been tested for clinical-scale production.48,95 As
mentioned previously, LCMV-LVs, GP64-LVs, and
RabV-LVs are also able to withstand the processes
used in GMP production. The notable exceptions
are LVs pseudotyped with gammaretroviral enve-
lopes, which cannot withstand ultracentrifugation.
Another important aspect of LV production is the
biosafety of the preparation. While LVs carry a risk
of insertional oncogenesis, they have undergone
several improvements to decrease that risk. These
improvements largely concern the vector backbone
and are beyond the scope of this review. Moreover,
as themajority of the clinically used LVs are derived
from HIV, there is also a risk of potential recombi-
nation, resulting in replication-competent virus.
Progressively, newer generations have minimized
this risk by separating different components for
vector production onto multiple plasmids. A three-
or four-plasmid system is considerably safer than a
one- or two-plasmid system. Another important
biosafety aspect to consider, particularly regarding
heterologous envelopes, is the pathogenicity of the
virus fromwhich they are derived. Particularly, the
use of envelopes from highly pathogenic viruses
such as EboZ, influenza, and alphaviruses needs to
be well regulated to minimize safety risk.
CONCLUSION
Since the advent of LVs, numerous studies have
altered their tropism. As reviewed in the preceding
sections, these modifications have mostly focused
on using envelopes from other viruses. There are
two key points that arise from these studies. First,
LVs are incredibly versatile, allowing pseudotyp-
ing by a diverse set of envelopes derived from
viruses across numerous families. Second, the di-
versity of viral envelopes, including the feasibility
of engineering their specificity, allows great cus-
tomization of LVs for every purpose. These many
guises of LVs make them powerful tools for cell-
specific transduction.
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